ریواستیگمین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "ریواستیگمین" in Persian language version.

refsWebsite

Global rank Persian rank

12nih.gov

4^th place

5^th place

7doi.org

2^nd place

1worldcat.org

5^th place

12^th place

1researchgate.net

120^th place

331^st place

1ucl.ac.uk

1,306^th place

1,796^th place

doi.org

Khoury, Rita; Rajamanickam, Jayashree; Grossberg, George T. (2018-01-08). "An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine". Therapeutic Advances in Drug Safety. SAGE Publications. 9 (3): 171–178. doi:10.1177/2042098617750555. ISSN 2042-0986. PMC 5810854. PMID 29492246.
Winblad, B.; Grossberg, G.; Frölich, L.; Farlow, M.; Zechner, S.; Nagel, J.; Lane, R. (2007). "IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease". Neurology. 69 (4 Suppl 1): S14–S22. doi:10.1212/01.wnl.0000281847.17519.e0. PMID 17646619.
Rosler, M.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stähelin, H. B.; Hartman, R.; Gharabawi, M. (1999). "Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw". BMJ. 318 (7184): 633–638. doi:10.1136/bmj.318.7184.633. PMC 27767. PMID 10066203.
Finkel, S. I. (2004). "Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease". Clinical Therapeutics. 26 (7): 980–990. doi:10.1016/S0149-2918(04)90172-5. PMID 15336465.
Rösler, M.; Retz, W.; Retz-Junginger, P.; Dennler, H. J. (1998). "Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease". Behavioural Neurology. 11 (4): 211–216. doi:10.1155/1999/168023. PMID 11568422.
Emre, M.; Aarsland, D.; Albanese, A.; Byrne, E. J.; Deuschl, G. N.; De Deyn, P. P.; Durif, F.; Kulisevsky, J.; Van Laar, T. (2004). "Rivastigmine for Dementia Associated with Parkinson's Disease" (PDF). New England Journal of Medicine. 351 (24): 2509–2518. doi:10.1056/NEJMoa041470. PMID 15590953.
Camps, P. Munoz-Torrero D. (Feb 2002). "Cholinergic drugs in pharmacotherapy of Alzheimer's disease". Mini Rev Med Chem. 2 (1): 11–25. doi:10.2174/1389557023406638. PMID 12369954.

nih.gov

pubmed.ncbi.nlm.nih.gov

Khoury, Rita; Rajamanickam, Jayashree; Grossberg, George T. (2018-01-08). "An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine". Therapeutic Advances in Drug Safety. SAGE Publications. 9 (3): 171–178. doi:10.1177/2042098617750555. ISSN 2042-0986. PMC 5810854. PMID 29492246.
Winblad, B.; Grossberg, G.; Frölich, L.; Farlow, M.; Zechner, S.; Nagel, J.; Lane, R. (2007). "IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease". Neurology. 69 (4 Suppl 1): S14–S22. doi:10.1212/01.wnl.0000281847.17519.e0. PMID 17646619.
Inglis, F. (2002). "The tolerability and safety of cholinesterase inhibitors in the treatment of dementia". International Journal of Clinical Practice. Supplement (127): 45–63. PMID 12139367.
Inglis, F. (2002). "The tolerability and safety of cholinesterase inhibitors in the treatment of dementia". International Journal of Clinical Practice. Supplement (127): 45–63. PMID 12139367.
Rosler, M.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stähelin, H. B.; Hartman, R.; Gharabawi, M. (1999). "Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw". BMJ. 318 (7184): 633–638. doi:10.1136/bmj.318.7184.633. PMC 27767. PMID 10066203.
Finkel, S. I. (2004). "Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease". Clinical Therapeutics. 26 (7): 980–990. doi:10.1016/S0149-2918(04)90172-5. PMID 15336465.
Rösler, M.; Retz, W.; Retz-Junginger, P.; Dennler, H. J. (1998). "Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease". Behavioural Neurology. 11 (4): 211–216. doi:10.1155/1999/168023. PMID 11568422.
Emre, M.; Aarsland, D.; Albanese, A.; Byrne, E. J.; Deuschl, G. N.; De Deyn, P. P.; Durif, F.; Kulisevsky, J.; Van Laar, T. (2004). "Rivastigmine for Dementia Associated with Parkinson's Disease" (PDF). New England Journal of Medicine. 351 (24): 2509–2518. doi:10.1056/NEJMoa041470. PMID 15590953.
Camps, P. Munoz-Torrero D. (Feb 2002). "Cholinergic drugs in pharmacotherapy of Alzheimer's disease". Mini Rev Med Chem. 2 (1): 11–25. doi:10.2174/1389557023406638. PMID 12369954.
Inglis, F. (2002). "The tolerability and safety of cholinesterase inhibitors in the treatment of dementia". International Journal of Clinical Practice. Supplement (127): 45–63. PMID 12139367.

ncbi.nlm.nih.gov

Khoury, Rita; Rajamanickam, Jayashree; Grossberg, George T. (2018-01-08). "An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine". Therapeutic Advances in Drug Safety. SAGE Publications. 9 (3): 171–178. doi:10.1177/2042098617750555. ISSN 2042-0986. PMC 5810854. PMID 29492246.
Rosler, M.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stähelin, H. B.; Hartman, R.; Gharabawi, M. (1999). "Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw". BMJ. 318 (7184): 633–638. doi:10.1136/bmj.318.7184.633. PMC 27767. PMID 10066203.

researchgate.net

Corey-Bloom, J.; Anand, R.; Veach, J. (1998). "A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease". International Journal of Geriatric Psychopharmacology. 1 (2): 55–65.

ucl.ac.uk

discovery.ucl.ac.uk

Emre, M.; Aarsland, D.; Albanese, A.; Byrne, E. J.; Deuschl, G. N.; De Deyn, P. P.; Durif, F.; Kulisevsky, J.; Van Laar, T. (2004). "Rivastigmine for Dementia Associated with Parkinson's Disease" (PDF). New England Journal of Medicine. 351 (24): 2509–2518. doi:10.1056/NEJMoa041470. PMID 15590953.

worldcat.org

Khoury, Rita; Rajamanickam, Jayashree; Grossberg, George T. (2018-01-08). "An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine". Therapeutic Advances in Drug Safety. SAGE Publications. 9 (3): 171–178. doi:10.1177/2042098617750555. ISSN 2042-0986. PMC 5810854. PMID 29492246.